Biblio Discovery — Demo Discovery Service

8 hasil untuk "F.R. Spinelli"

Menampilkan 1–8 · 0,53 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Gender equality in Rheumatology

    S.L. Bosello; M.S. Chimenti; P. Conigliaro dkk.

    Reumatismo, Vol. 71 No. 4 · 2020 · Inggris · DOAJ Scopus

    Not available

    Juga tersedia di: DOAJ

  2. Artikel Jurnal

    Evaluation of diagnostic and therapeutic delay in patients with rheumatoid arthritis and psoriatic arthritis

    M. Iacovantuono; S. Ferrigno; P. Conigliaro dkk.

    Reumatismo, Vol. 76 No. 1 · 2024 · Italia · DOAJ Scopus

    Objective. A monocentric cross-sectional study recruiting rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients residing in the Lazio region, Italy, to assess factors related to diagnostic delay and treatment accessibility. Methods. Clinical/serological data, including the time between…

  3. Artikel Jurnal

    Pain and systemic lupus erythematosus

    M. Di Franco; M.P. Guzzo; F.R. Spinelli dkk.

    Reumatismo, Vol. 66 No. 1 · 2014 · Italia · DOAJ Scopus

    Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by heterogeneous clinical manifestations involving virtually the entire body. The pain in SLE can have different causes. The SLE classification criteria include mainly the musculoskeletal manifestations of pain, which are…

  4. Artikel Jurnal

    Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

    M. Di Franco; L. Magrini; S. Truglia dkk.

    Reumatismo, Vol. 61 No. 2 · 2011 · Italia · DOAJ Scopus

    The treatment of rheumatoid arthritis (RA) has evolved over the past decade with the introduction of anti-tumor necrosis factor (TNF) α agents, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing joint destruction (1-3). However, some patients do not…

  5. Artikel Jurnal

    Janus kinase inhibitors: between prescription authorization and reimbursability

    F.R. Spinelli; F. Conti; R. Caporali dkk.

    Reumatismo, Vol. 75 No. 4 · 2023 · Italia · DOAJ Scopus

    Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.

  6. Artikel Jurnal

    Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort

    E. Molteni; C. Pirone; F. Ceccarelli dkk.

    Reumatismo, Vol. 76 No. 2 · 2024 · Italia · DOAJ Scopus

    Objective. Data from trials demonstrated that abatacept (ABA) has a good safety and efficacy profile in treating rheumatoid arthritis. We have studied the retention rate of ABA in a real-life cohort of patients with rheumatoid arthritis. Methods. This is a monocentric, retrospective study including…

  7. Artikel Jurnal

    PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors

    C. Garufi; S. Mancuso; F. Ceccarelli dkk.

    Reumatismo (2024) · 2024 · Italia · DOAJ Scopus

    Objective. Patients Acceptable Symptom State (PASS) is a single dichotomized question assessing health satisfaction. We aimed to investigate PASS achievement within 4 weeks of treatment with Janus kinase (JAK) inhibitors (Jakinibs) and its association with treatment response after 4 and 12 weeks in…